Our scientists are listed as co-inventors with our clients on many patents.

2019 Patents

Previous Years

  • 2018
    • Thiophene Derivatives as Antiviral Agents. WO/2018/122317.
    • (4-(([1,2,4]Triazolo[4,3-A]Pyridine-6-Yl)Oxy)-1,2,3,4-Tetrahydronaphthalen-1-Yl) Ureido Derivatives As Anti-Inflammatory P38 Mapk Inhibitors For Treating Diseases Of The Respiratory Tract. WO/2018/224423.
    • 1-(2-Azaspiro[3.3]Heptan-6-Yl)-5,6-Dihydro-4h-Benzo[F][1,2,4]Triazolo[4,3-A][1,4]Diazepine Derivatives As V1a Receptor Antagonists For Treating Neuropsychological Disorders. WO/2018/226769.
    • Compounds Useful As RET Inhibitors. WO/2018/189553.
    • Isoquinolines as Inhibitors of HPK1. WO/2018/183964.
    • Isoindolinone Inhibitors of the Mdm2-P53 Interaction and Process for Making Them. WO/2018/178691.
    • Naphthyridines as Inhibitors of HPK1. WO/2018/183956.
    • Chemical Compounds as Antibiotics. WO/2018/172423.
    • Azaindoles as Inhibitors of HPK1. WO/2018/167147.
    • Tyrosine Amide Derivatives as Rho-Kinase Inhibitors. WO/2018/138293.
    • Bicyclic Dihydropyrimidine-Carboxamide Derivatives as Rho-Kinase Inhibitors. WO/2018/115383.
    • Oxadiazolones as Transient Receptor Potential Channel Inhibitors. WO/2018/096159.
    • Pyridazine Derivatives as RORc Modulators. WO/2018/083105.
    • 8-(Azetidin-1-Yl)-[1,2,4]Triazolo[1,5-A]Pyridinyl Compounds, Compositions and Methods of Use Thereof. WO/2018/046409.
    • Hydroxyquinolinone Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity. WO/2018/011090.
    • Cyanoindoline Derivatives as NIK Inhibitors. WO/2018/002219.
    • Heteroaromatic Derivatives as NIK Inhibitors. WO/2018/002217.
  • 2017
    • Heteroaryl Estrogen Receptor Modulators and Uses Thereof. WO/2017/216279.
    • Heterocyclic Compounds for Use in the Treatment of a Disease in Which HNE Is Implicated. WO/2017/207433.
    • Novel Compounds. WO/2017/207432.
    • Imidazolone Compounds as Human Neutrophil Elastase Inhibitors. WO/2017/207430.
    • Crystal of Quinoline Derivative. WO/2017/199903.
    • Pyrazole Derivatives, Compositions And Therapeutic Use Thereof. WO/2017/191098.
    • Chemical Compounds as Inhibitors of Kinase Activity. WO/2017/137535.
    • New 6-Membered Heteroaromatic Substituted Cyanoindoline Derivatives as NIK Inhibitors. WO/2017/125534.
    • New Substituted Cyanoindoline Derivatives as NIK Inhibitors. WO/2017/125530.
    • 1-(3-Tert-Butyl-2h-Pyrazol-5-Yl Or 5-Tert-Butyl-Isoxaol-3-Yl)-3-(4-([1,2,4]Triazolo[4,3-A]Pyridin-6-Yloxy)-1,2,3,4-Tetrahydro-Naphthalenyl) Urea Derivatives and Their Use as P38 Mapk Inhibitors. WO/2017/108738.
    • 1-(3-Tert-Butyl-Phenyl)-3-(4-([1,2,4]Triazolo[4,3-A]Pyridin-6-Yloxy)-1,2,3,4-Tetrahydro- Naphthalen-1-Yl)-Urea Derivatives and Their Use as P38 Mapk Inhibitors. WO/2017/108737.
    • N-[3-(3-{4-[[1,2,4]Triazolo[4,3-A]Pyridin-6-Yloxy]-1,2,3,4-Tetrahydro-Naphthalen-1-Yl} -Ureido)-Phenyl]-Methanesulfonamide Derivatives and Their Use as P38 Mapk Inhibitors. WO/2017/108736.
    • Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity. WO/2017/093208.
    • Isoindolinone Inhibitors of the Mdm2-P53 Interaction Having Anticancer Activity. WO/2017/055860.
    • Isoindolinone Inhibitors of the Mdm2-P53 Interaction Having Anticancer Activity. WO/2017/055859.
    • Tricyclic PI3k Inhibitor Compounds and Methods of Use. WO/2017/042182.
    • Aryl Sultam Derivatives as RORc Modulators. WO/2017/005900.
    • Aryl Sultam Derivatives as RORc Modulators. WO/2017/005668.
    • Benzoxazepin Oxazolidinone Compounds and Methods of Use. WO/2017/001645.
    • Benzoxazepin Oxazolidinone Compounds and Methods of Use. WO/2017/001658.
  • 2016
    • Aminoester Derivatives Useful in the Treatment of COPD. WO/2016/193240.
    • Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity. WO/2016/193241.
    • Aminoester Derivatives. WO/2016/193244.
    • Heterocyclic Estrogen Receptor Modulators and Uses Thereof. WO/2016/189011.
    • Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. WO/2016/179550.
    • Histone Deacetylase Inhibitors and compositions and Methods of Use Thereof. WO/2016/179554.
    • Pyridazine Derivatives as RORc Modulators. WO/2016/177686.
    • Pyridazine Derivatives as RORc Modulators. WO/2016/177710.
    • Pyridazine Derivatives as RORc Modulators. WO/2016/177760.
    • Aminoester Derivatives. WO/2016/177849.
    • Amino-substituted Heterocyclic Derivatives as Sodium Channel Inhibitors. WO/2016/170009.
    • Amido Thiadiazole Derivatives as NADPH Oxidase Inhibitors. WO/2016/098005.
    • Estrogen Receptor Modulators and Uses Thereof. WO/2016/0304450.
    • Pyrazolopyridazines and Methods for Treating Retinal-Degenerative Diseases and Hearing Loss Associated with Usher Syndrome. WO/2016/0272647.
    • Antibacterial Thiazolecarboxylic Acids. WO/2016/0272601.
    • Triazolopyridine Compounds and Methods of Use Thereof. WO/2016/139212.
    • Preparation of thiazole sulfonamides as metallo-β-lactamase inhibitors for the treatment and prevention of bacterial infections in combination with β-lactam antibiotics. GB 2533136.
    • Tetrahydro-Pyrido[3,4-B]Indole Estrogen Receptor Modulators and Uses Thereof. WO/2016/097072.
    • Estrogen Receptor Modulators and Uses Thereof. WO/2016/097071.
    • Novel Compounds. WO/2016/096638.
    • New Compounds as Nik Inhibitors. WO/2016/062792.
    • New Pyrazole Derivatives as Nik Inhibitors. WO/2016/062791.
    • New Pyrazolopyrimidine Derivatives as Nik Inhibitors. WO/2016/062790.
    • New Thienopyrimidine Derivatives as Nik Inhibitors. WO/2016/062789.
  • 2015
    • Tetrahydrotriazolopyrimidine Derivatives, Pharmaceutical Compositions Containing the Same and Uses. WO/2015/189362.
    • Novel Compounds. WO/2015/188866.
    • Histone Deacetylase Inhibitors and Compositions and Methods of use Thereof. WO/2015/187542.
    • Carbamate Derivatives which are both Phosphodiesterase 4 (PDE4) Enzyme Inhibitors and Muscarinic M3 Receptor Antagonists. WO/2015/185650.
    • Aminoester Derivatives. WO/2015/185649.
    • 3,5-Dichloro,4-(3,4-(Cyclo-)Alkoxyphenyl)-2-Arbonyloxy)Ethyl)Pyridine Derivatives as PDE -4 Inhibitors. WO/2015/185130.
    • 3,5-Dichloro,4-(3,4-(Cyclo-)Alkoxyphenyl)- 2-Carbonyloxy)Ethyl)Pyridine Derivatives as PDE-4 Inhibitors. WO/2015/185128.
    • 5-Chloro-2-Difluoromethoxyphenyl Pyrazolopyrimidine Compounds which are Jak Inhibitors.WO/2015/177326.
    • Benzene Sulfonamide Derivatives and their use as RORc Modulators. WO/2015/177325.
    • 6-Substituted Imidazo[1,2-A]Pyrazinecarboxamides and Use Thereof. WO/2015/165933.
    • Imidazo[1,2-A] Pyridines as Stimulators of Soluble Guanylate Cyclase for Treating Cardiovascular Disease. WO/2015/165931.
    • Fused Imidazole Compounds. WO/2015/115673.
    • (2S)-N-[(1S)-1-Cyano-2-Phenylethyl]-1,4-Oxazepane-2-Carboxamides as Dipeptidyl Peptidase I Inhibitors. WO/2015/110826
    • Aryl Sultam Derivatives as RORc Modulators. WO/2015/104356.
    • Aryl Sultam Derivatives as RORc Modulators. WO/2015/104354.
    • Thiazolopyridine Compounds, Compositions and Their Use as Tyk2 Kinase Inhibitors. WO/2015/091584.
    • Tetrahydrotriazolopyrimidine Derivatives as Human Neutrophil Elastase Inhibitors. WO/2015/091281.
    • Benzhydryl Derivatives for the Treatment of Respiratory Diseases. WO/2015/082619.
    • Heteroaryl Derivatives for the Treatment of Respiratory Diseases. WO/2015/082616.
    • Heteroaryl-Ether Fused Azadecalin Glucocorticoid Receptor Modulators. WO/2015/077537.
    • New 3-(1H-Pyrazol-4-Yl)-1H-Pyrrolo[2,3-c]Pyridine Derivatives as NIK Inhibitors. WO/2015/044269.
    • New 1-(4-Pyrimidinyl)-1H-Pyrrolo[3,2-c]Pyridine Derivatives as NIK Inhibitors. WO/2015/044267.
    • Triazolopyridine Compounds, Compositions and Methods of Use Thereof. WO/2015/032286.
  • 2014
    • Azaindazole Compounds as Inhibitors of T790M-Containing EGFR Mutants. WO/2014/210354.
    • Antibacterial Thiazolecarboxylic Acids. WO/2014/198849.
    • Kinase Inhibitors. WO/2014/195402.
    • Kinase Inhibitors. WO/2014/195400.
    • Derivatives of (1, 2, 4) Triazolo (4, 3–A) Pyridine as p38-MAP Kinase Inhibitors. WO/2014/194956.
    • 3-(2-Aminopyrimidin-4-yl)-5-(3-Hydroxypropynyl)-1H-Pyrrolo[2,3-C]Pyridine Derivatives as NIK Inhibitors for the Treatment of Cancer. WO/2014/174021.
    • Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. WO/2014/159224.
    • Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. WO/2014/159218.
    • Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. WO/2014/159214.
    • Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. WO/2014/159210.
    • Aryl Sulfamide and Sulfamate Derivatives as RORc Modulators. WO/2014/140059.
    • Novel Compounds. WO/2014/095700.
    • Benzyl Sulfonamide Derivatives as Rorc Modulators. WO/2014/090712.
    • Benzyl Sulfonamide Derivatives as Rorc Modulators. WO/2014/090710.
    • Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity. WO/2014/086927.
    • Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity. WO/2014/086924.
    • Phenylethylpyridine Derivatives as PDE4-Inhibitors. WO/2014/086855.
    • Phenylethylpyridine Derivatives as PDE4-Inhibitors. WO/2014/086852.
    • Phenylethylpyridine Derivatives as PDE4-Inhibitors. WO/2014/086849.
    • Aminopyrimidine Compounds as Inhibitors of T790M Containing EGFR Mutants. WO/2014/081718.
    • Tricyclic Compounds for Use in the Treatment and/or Control of Obesity. WO/2014/071369.
    • Tricyclic Compounds and Methods of Making and Using Same. WO/2014/071363.
    • Pyrazolopyridazines and Methods for Treating Retinal-Degenerative Diseases and Hearing Loss Associated With Usher Syndrome. WO/2014/066836.
    • Pyrazolopyridazines and Methods for Treating Retinal-Degenerative Diseases and Hearing Loss Associated With Usher Syndrome. WO/2014/066835.
    • Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. WO/2014/048939.
    • Dioxino- and Oxazin-[2,3-D]Pyrimidine Pi3k Inhibitor Compounds and Methods of Use. WO/2014/033196.
    • Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. WO/2014/014900.
    • Fused Triazole Derivatives as Gamma Secretase Modulators. WO/2014/012614.
    • Aryl Sultam Derivatives as RORc Modulators. WO/2014/009447.
    • Inhibition of Enzymes. WO/2014/009425.
  • 2013
    • Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators. WO/2013/177559.
    • Pyrazole Aminopyrimidine Derivatives as LRRK2 Modulators for use in the Treatment of Parkinson's Disease. WO/2013/164323. 
    • Pyrazole Aminopyrimidine Derivatives as LRRK2 Modulators. WO/2013/164321.
    • Phenyl Heterocycloalkyl Glucocorticoid Receptor Modulators. WO/2013/130420.
    • Tricyclic Sulfonamide Compounds and Methods of Making and Using Same. WO/2013/109739.
    • Tricyclic Sulfonamide Compounds and Methods of Making and Using Same. WO/2013/109735.
    • Kinase Inhibitors. WO/2013/083606.
    • Kinase Inhibitors. WO/2013/083604.
    • Derivatives of 4-Hydroxy-1,2,3,4-Tetrahydronaphthalen-1-yl Urea and Their Use in the Treatment of, Inter Alia, Diseases of the Respiratory Tract. WO/2013/083206.
    • Aminopyrimidine derivatives as LRRK2 modulators WO/2013/079505
    • 2-(phenyl or pyrid-3-yl) aminopyrimidine derivatives as kinase LRRK2 modulators for the treatment of Parkinson's Disease WO/2013/079495
    • 2-phenylaminopyrimidine derivatives as kinase LRRK2 modulators for the treatment of Parkinson's Disease WO/2013/079494
    • Aminopyrimidine derivatives as LRRK2 modulators WO/2013/079493
    • Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. WO/2013/045461
    • Fsh receptor antagonists. WO/2013/041461
    • Fsh receptor antagonists. WO/2013/041458
    • N-piperidin-4-yl derivatives. WO/2013/041457
    • Tetrahydrotriazolopyrimidine Derivatives as Human Neutrophil Elastase Inhibitors. WO/2013/037809.
    • Tricyclic Heterocyclic Compounds, Compositions and Methods of Use Thereof as Jak Inhibitors. WO/2013/007768.
    • Fused Tricyclic Compounds for Use as Inhibitors of Janus Kinases. WO/2013/007765.
  • 2012
    • Compounds having muscarinic receptor antagonist and beta-2 andrenergic receptor agonist activity. WO/2012/168359
    • Compounds having muscarinic receptor antagonist and beta-2 andrenergic receptor agonist activity. WO/2012/168349
    • Tricyclic pyrazole sulfonamide compounds and methods of making and using same. WO/2012/154679.
    • Tricyclic sulfonamide compounds and methods of making and using same. WO/2012/154678.
    • Partially saturated tricyclic compounds and methods of making and using same. WO/2012/154676.
    • Pyrazolopyridines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome. WO/2012/148994
    • Novel compound useful for the treatment of degenerative and inflammatory diseases. WO/2012/146659
    • Novel compound useful for the treatment of degenerative and inflammatory diseases. WO/2012/146657.
    • Pyrimidine cyclohexyl glucocorticoid receptor modulators. WO/2012/129074.
    • Benzoxapin compounds selective for PI3K P110 delta and methods of use. WO/2012/126901.
    • Heterocyclic compounds as PI3 kinase Inhibitors. WO/2012/107465.
    • Tetrazole Compounds and Methods of Making and Using Same. WO/2012/103333.
    • Histone deacetylase inhibitors and compositions and methods of use thereof. WO/2012/103008.
    • Tricyclic pyrazinone compounds, compositions and methods of use thereof as Janus Kinase inhibitors. WO/2012/085176.
    • Tricyclic pi3k inhibitor compounds and methods of use. WO/2012/082997.
    • Pyrazolopyridines and pyrazolopyridines and their use as Tyk2 inhibitors. WO/2012/066061.
    • Pyrazole aminopyrimidine derivatives as LRRK2 modulators. WO/2012/062783
    • Sulphonamide Compounds and Methods of Making and Using Same. WO/2012/051318.
    • Bacteria topoisomerase II inhibiting 2-ethylcarbamoylamino-1,3-benzothiazol-5-yls. WO/2012/045124
    • Azabenzothiazole compounds, compositions and methods of use. WO/2012/035039.
    • Tricyclic Compounds and Methods of making and using same. WO/2012/012642.
    • 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (S1P) receptors. WO/2012/004287
  • 2011
    • Urea Derivatives and Their Therapeutic Use in the Treatment of, Inter Alia, Diseases of the Respiratory Tract. WO/2011/154738.
    • Compounds. WO/2011/154678.
    • Aminopyrimidine derivatives as LRRK2 modulators. WO/2011/151360.
    • 3, 3-Disubstituted-( 8-Aza-Bicyclo [3.2.1] Oct-8-yl)-[5-(1H-Pyrazol-4-yl)-Thiophen-3-yl] Methanones as Inhibitors of 11 (Beta)-HSD1. WO/2011/135276.
    • Preparation of 4H-1,2,4]triazolo[5,1-b]pyrimidin-7-one derivatives as CCR2b receptor antagonists. WO/2011/114148.
    • Pyrimidine Derivatives and Their Use in the Treatment of Respiratory Diseases Such as COPD. WO/2011/110859.
    • Pyrimidine Derivatives and Their Use in the Treatment of Respiratory Diseases Such as COPD. WO/2011/110858.
    • Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions. WO/2011/104340.
    • Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions. WO/2011/104338.
    • Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions. WO/2011/104337.
    • 3. 4 - [cycloalkyloxy (hetero) arylamino] thieno [2, 3 - D] pyrimidines having MNKL/ MNK2 inhibiting activity for pharmaceutical compositions. WO/2011/104334.
    • Crystalline Acid Addition Salts of (5R)-Enantiomer of Pioglitazone. WO/2011/098746.
    • 1,2,4-triazine-4-amine derivatives. WO/2011/095625.
    • New anti-malarial agents. WO/2011/086531.
    • Tricyclic heterocyclic compounds, compositions and methods of use thereof. WO/2011/086053.
    • 1,7 diazacarbazoles and their use in the treatment of cancer. WO/2011/073263.
    • Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors. WO/2011/058113.
    • Fused bicyclic pyrazole derivatives as kinase inhibitors. WO/2011/058112.
    • Aminopurine derivatives as kinase inhibitors. WO/2011/058111.
    • Quinoline and quinoxaline derivatives as kinase inhibitors. WO/2011/058110.
    • Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors WO/2011/058109.
    • Quinoline and quinoxaline derivatives as kinase inhibitors. WO/2011/058108.
    • Sulphone Compounds and Methods of Making and Using Same. WO/2011/044506.
    • Benzoxazepin Pi3k Inhibitor Compounds and Methods of Use. WO/2011/036284.
    • Benzoxazepin Pi3k Inhibitor Compounds and Methods of Use. WO/2011/036280.
    • Pharmaceutical compounds. WO/2011/033265.
    • 4-Phenyl-piperidin-1-yl)-[5-1H-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use. WO/2011/033255.
    • Enantiomeric Resolution Method. WO/2011/015868.
    • Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurogenerative diseases. WO/2011/015573.
    • Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurogenerative diseases. WO/2011/015572.
  • 2010
    • 5R-5-Deuterated Glitazones for Respiratory Disease Treatment. WO/2010/150014.
    • Amido-isothiazole compounds and their use as inhibitors of 11beta-Hsd1 for the treatment of metabolic syndrome and related disorders. WO/2010/146338.
    • Indole Derivatives as Ligands of Crth2 Receptors. WO/2010/142934.
    • Janus Kinase Inhibitor Compounds and Methods.  WO/2010/142752.
    • Pyrazole oxadiazole derivatives as S1P1 agonists. WO/2010/142628.
    • Bicyclic Pyrimidine Pi3k Inhibitor Compounds Selective for P110 Delta, and Methods of Use. WO/2010/138589.
    • Bicyclic Indole-Pyrimidine Pi3k Inhibitor Compounds Selective for P110 Delta, and Methods of Use. WO/2010/136491.
    • Fused bicyclic pyrazole derivatives as kinase inhibitors. WO/2010/133836.
    • Pyridylurea Derivatives and Their Therapeutic Use. WO/2010/131030.
    • Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives. WO/2010/123933.
    • Compounds, compositions and methods comprising pyridazine sulphonamide derivatives. WO/2010/123822.
    • Methods and means for treatment of osteoarthritis. WO/2010/115841.
    • Preparation of triazines as phosphoinositide 3-kinase (PI3K) inhibitors. WO/2010/100405.
    • Triazolopyridine Derivatives as P38 Map Kinase Inhibitors. WO/2010/094956.
    • Pyrimidopyridazine Derivatives Useful as P38 Inhibitors. WO/2010/094955.
    • Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation. WO/2010/094734.
    • Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation. WO/2010/094733.
    • Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation. WO/2010/094732.
    • Fused pyridine and pyrazine derivatives as kinase inhibitors. WO/2010/092340.
    • Dimeric Pyrrolopyrimidinedione and Its Use in Therapy of Respiratory Diseases. WO/2010/086638.
    • Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient. WO/2010/071582.
    • Pharmaceutical product comprising a muscarinic receptor antagonist and a B2-adrenoceptor agonist. WO/2010/071581.
    • Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders. WO/2010/067102.
    • Preparation of fused pyrazines as phosphoinositide 3-kinase (PI3K) inhibitors. WO/2010/052448.
    • Compounds, compositions and methods comprising imidazole and triazole derivatives. WO/2010/033626.
    • Thienopyrimidines for pharmaceutical compositions. WO/2010/023181.
    • 2-hydroxy-ethanesulfonate salt. WO/2010/019099.
    • Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist. WO/2010/019098.
    • Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient. WO/2010/019097.
    • Heterocyclic compounds used in the treatment of diseases where enhanced M3 receptor activation is implicated. WO/2010/018352.
    • Nitrogen containing heterocyclic compounds useful as bifunctional modulators of M3 receptors and beta-2 receptors. WO/2010/015792.
    • Novel compounds useful for the treatment of degenerative and inflammatory diseases. WO/2010/010190.
    • Novel compounds useful for the treatment of degenerative and inflammatory diseases. WO/2010/010189.
    • Novel compounds useful for the treatment of degenerative and inflammatory diseases. WO/2010/010188.
    • [1, 2, 4] triazolo [1, 5-a] pyridines as JAK inhibitors. WO/2010/010184.
    • Bicyclic heterocycles as Mek kinase inhibitors. WO/2010/003025.
    • Isoindolone derivatives as Mek kinase inhibitors and methods of use. WO/2010/003022.
  • 2009
    • Triazolo JAK Inhibitor Compounds and Methods. WO/2009/155551.
    • Diazacarbazoles as checkpoint kinase 1 inhibitors and their preparation and use in the treatment of cancer. WO/2009/151598.
    • Diazacarbazoles as checkpoint kinase 1 inhibitors and their preparation and use in the treatment of cancer. WO/2009/151589.
    • Pharmaceutical Product Comprising a Muscarinic Receptor Antagonist and a Βeta2-Adrenoceptor Agonist. WO/2009/139708.
    • Pharmaceutical Product Comprising a Muscarinic Receptor Antagonist and a Second Active Ingredient. WO/2009/139707.
    • Imidazo [2,1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents. WO/2009/138796.
    • Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases. WO/2009/138794.
    • Substituted quinazolines. WO/2009/138792.
    • Substituted quinazolines as blood platelet lowering agents. WO/2009/138789.
    • Substituted quinazolines. WO/2009/138788.
    • Quinuclidine derivatives as muscarinic M3 receptor antagonists. WO/2009/138707.
    • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases. WO/2009/135885.
    • Compounds, compositions and methods comprising triazine derivatives. WO/2009/131958.
    • Compounds, compositions and methods comprising oxadiazole derivatives. WO/2009/131957.
    • Compounds, compositions and methods comprising triazole derivatives. WO/2009/131956.
    • Compounds, compositions and methods comprising oxadiazole derivatives. WO/2009/131954.
    • Compounds, compositions and methods comprising thiazole derivatives. WO/2009/131952.
    • Compounds, compositions and methods comprising isoxazole derivatives. WO/2009/131951.
    • High-throughput cell-based CFTR assay. WO/2009/131948.
    • Compounds, compositions and methods comprising pyridazine derivatives. WO/2009/131947.
    • Preparation of amido-thiophene compounds as 11β-HSD1 inhibitors. WO/2009/112845.
    • 2-(9H-xanthen-9-yl)-oxazol Derivatives as M3 Muscarinic Receptor Antagonists for the Treatment of Asthma and Chronic Obstructive Lung Disease. WO/2009/098455.
    • Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists. WO/2009/098453.
    • Compounds. WO/2009/098448
    • 5-Anilinoimidazopyridines and Methods of Use. WO/2009/085983.
    • 8-Anilinoimidazopyridines and Their Use as Anti-Cancer and/or Anti-Inflammatory Agents. WO/2009/085980.
    • Azaindolizines and Methods of Use. WO/2009/082687.
    • Quinoxaline and quinoline derivatives as kinase inhibitors. WO/2009/081105.
    • Triazole Oxadiazoles Derivatives. WO/2009/080663.
    • Preparation of substituted amidothiophene derivatives for use as 11-beta-hsd1 inhibitors. WO/2009/074789.
    • A substituted thieno-pyridinone kinase inhibitor. WO/2009/071901.
    • Fused thiazole and thiophene derivatives as kinase inhibitors. WO/2009/071895.
    • Purine Derivatives Useful as PI3 inhibitors. WO/2009/053716.
    • Thienopyrimidines Derivatives Useful as PI3 inhibitors. WO/2009/053715.
    • Triazolopyridine compounds and their use as ASK inhibitors. WO/2009/027283.
  • 2008
    • N-Substituted Azaindoles and Methods of Use. WO/2008/157179.
    • Pharmaceutical Compounds. WO/2008/152394.
    • Pharmaceutical Compounds. WO/2008/152390.
    • Pharmaceutical Compounds. WO/2008/152387.
    • Bicyclo [2.2.1] Hept-7-ylamine Derivatives and Their Use in the Treatment of Diseases and Conditions in which M3 Muscarinic Receptor Activity and Beta-Adrenergic Activity are Implicated. WO/2008/149110.
    • Bicyclo [2.2.1] Hept- 2-ylamine Derivatives and Their Use. WO/2008/149053.
    • Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms. WO/2008/142384.
    • Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative and inflammatory diseases. WO/2008/138843.
    • Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases. WO/2008/138842.
    • 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases. WO/2008/129080.
    • Pharmaceutical Compounds. WO/2008/125839.
    • Pharmaceutical Compounds. WO/2008/125833.
    • CFTR inhibitor compounds and uses thereof. WO/2008/121877.
    • Antimicrobial compounds based upon 4-aminoquinoline as drugs, preservatives, and sterilants. WO/2008/117079.
    • Use of N2-phenylamides as herbicides. WO/2008/110278.
    • Quinolinone derivatives as parp and tank inhibitors. WO/2008/107478.
    • New salt. WO/2008/096149.
    • Combinations with a muscarinic receptor antagonist. WO/2008/096136.
    • Nitrogen containing heterocyclic compounds useful as bifunctional modulators of M3 receptors and beta-2 receptors. WO/2008/096129.
    • New chemical compounds. WO/2008/096127.
    • Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist. WO/2008/096126.
    • 1-Aminomethyl-1-Phenyl-Cyclohexane Derivatives as DPP-IV Inhibitors. WO/2008/077597.
    • Pyridine benzamides and pyrazine benzamides used as PKD inhibitors. WO/2008/074997.
    • Aza-indolyl Compounds and Methods of Use. WO/2008/067481.
    • Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases. WO/2008/065199.
    • Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases. WO/2008/065198.
    • Preparation of 4-Substituted 2-Amino-Benzo[4,5]Pyrimidine Derivatives. WO/2008/062013.
    • Novel compounds useful for the treatment of degenerative and inflammatory diseases. WO/2008/055959.
    • Aza-Benzofuranyl Compounds and Methods of Use. WO/2008/024725.
    • Aza-Benzothiophenyl Compounds and Methods of Use. WO/2008/024724.
    • Nitrogen Containing Heterocyclic Compounds Useful as M3-Receptor Modulators. WO/2008/023157.
  • 2007
    • Antibacterial compositions. WO/2007/148093.
    • Preparation of pteridine derivatives as cathepsin inhibitors.WO/2007/148064.
    • Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in MCH-1 mediated diseases. WO/2007/141200.
    • Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases. WO/2007/138072.
    • Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases. WO/2007/131991.
    • Pyrimidine Derivatives as PI3k Inhibitors. WO/2007/122410.
    • Trisubstituted 1,2,4-triazoles. WO/2007/118903.
    • Organic Compounds. WO/2007/115821.
    • Compositions and Methods for Modulating Gated Ion Channels. WO/2007/115410.
    • Compositions and Methods for Modulating Gated Ion Channels. WO/2007/115409.
    • Azetidine Amino Pyrimidine Compounds for the Treatment of Inflammatory Disorders. WO/2007/090854.
    • Enantiomers of Amino Pyrimidine Compounds for the Treatment of Inflammatory Disorders. WO/2007/090853.
    • Amino Pyrimidine Compounds for the Treatment of Inflammatory Disorders. WO/2007/090852.
    • Pyridine-, isoxazole, thiophenecarboxamide compounds having activity at the glycine transporter GlyT1 and uses thereof. WO/2007/080159.
    • Condensed heterocyclic compounds useful as DPP-IV inhibitors. WO/2007/071738.
    • Novel substituted pyrazinone derivatives for use in MCH-1 mediated diseases. WO/2007/071646.
    • Use of pyrroloquinoline compounds to kill clinically latent microorganisms. WO/2007/054693.
    • Pyrimidine Compounds for the Treatment of Inflammatory Disorders. WO/2007/045867.
    • 1,5-Substituted Tetrazoles as Therapeutic Compounds. WO/2007/029021.
    • EP2 receptor agonists. WO/2007/017687.
  • 2006
    • Tricyclic spiro derivatives as CRTH2 modulators. WO/2006/125784.
    • Piperazine derivatives as GlyT1 inhibitors. WO/2006/094843.
    • Acylated piperidines as glycine transporter inhibitors. WO/2006/094842.
    • Preparation of acylated piperazines as glycine transporter inhibitors. WO/2006/094840.
    • Substituted bis aryl and heteroaryl compounds as selective 5-HT2a antagonists. WO/2006/086705.
    • Compounds which bind to the active site of protein kinase enzymes. WO/2006/072792.
    • Oxygen containing heterocycles as glycine transporter inhibiting compounds. WO/2006/067437.
    • Glycine transport inhibitors. WO/2006/067430.
    • Glycine transport inhibitors. WO/2006/067423.
    • Glycine transport inhibitors. WO/2006/067417.
    • Glycine transport inhibitors. WO/2006/067414.
    • Preparation of 4H-spiro[1,3]benzodioxine-2,4'-piperidine derivatives and related compounds. WO/2006/067224.
    • Preparation of thienopyridine derivatives as potassium channel inhibitors for the treatment of arrhythmia and diabetes. WO/2006/061642.
    • Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes. WO/2006/051311.
    • 2, 6-substituted-4-monosubstituted amino-pyrimidines as prostaglandin D2 receptor antagonists. WO/2006/044732.
    • Pyrazolo[1,5-a]pyrimidine derivative. WO/2006/016715.
    • Tetrahydronaphthalene derivatives as glucocorticoid receptor modulators. WO/2006/015870.
    • Modified Pyrimidine Glucocorticoid Receptor Modulators.WO/2006/014394.
    • Pyridinylamines and their preparations, pharmaceutical compositions and use for prophylaxis or treatment of various diseases. WO/2006/010637.
    • Novel indazole carboxamides and their use. WO/2006/002434.
  • 2005
    • Furanopyrimidine compounds effective as potassium channel inhibitors. WO/2005/121149.
    • Preparation of triazacyclopenta[b]naphthalene derivatives as modulators of glucocorticoid receptor. WO/2005/087769.
    • Preparation of phenylindan amino acid derivatives as inhibitors of glycine transport. WO/2005/087708.
    • EP2 receptor agonists. WO/2005/080367.
    • Azadecalin Glucocorticoid Receptor Modulators. WO/2005/070893.
    • Preparation of spiro(beta-carbolinepyrrolidines) and related compounds as growth hormone secretagogue receptor (GHSR) antagonists. WO/2005/048916.
    • Novel Diazaspiroalkanes and Their Use for Treatment of CCR-8 Mediated Diseases. WO/2005/040167.
    • Furan Derivatives as EP4 Receptor Antagonists. WO/2005/037812.
    • Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases. WO/2005/026129.
    • Imidazo[1,5-a] pyradine or imidazo[1,5-a] piperidine derivatives and their use for the preparation of medicament against 5-HT2A receptor-related disorders. WO/2005/021545.
    • The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-HT2A receptor-related disorders. WO/2005/021505.
    • 5-HT2B Receptor Antagonists. WO/2005/012263.
  • 2004
  • 2003
    • Preparation of pesticidal pyridinecarboxamides. WO/2003/097605.
    • 2-Oxazolamines and Their Use as 5-HT2B Receptor Antagonists. WO/2003/068226.
    • Heteroaryl compounds useful as inhibitors of GSK-3. WO/2003/066629.
    • Aryloxyphenyl and Arylsulfanylphenyl Derivatives. WO/2003/053942.
    • Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity. WO/2003/020282.
    • Preparation of 2-(benzoylamino)benzoic acid derivatives as modulators of the PPARalpha and PPARgamma receptors. WO/2003/004458.
  • 2002
    • Preparation of aryl-substituted N-hydroxy amides with sulfonamide linkages as HDAC inhibitors for treatment of proliferative conditions. WO/2002/030879.
    • Novel pyridazine compounds for the treatment of diabetes. WO/2002/026743.
    • Preparation of carbamic acid compounds comprising an ether linkage as HDAC inhibitors. WO/2002/026703.
    • Carbamic acid compounds comprising an amide linkage as HDAC inhibitors. WO/2002/026696.